AIM ImmunoTech is trading 5% down at $0.26 following shareholder approval of a potential reverse stock split and significant new share issuances tied to warrants and promissory notes.
- The July 15 special meeting results have triggered investor concerns regarding equity dilution and capital-structure risks.
- Shares are facing downward pressure despite broader strength in the biotechnology sector and a generally weak equity market backdrop.